HomeInsightsStock Comparison

Bliss Gvs Pharma Ltd vs Medicamen Biotech Ltd Stock Comparison

Bliss Gvs Pharma Ltd vs Medicamen Biotech Ltd Stock Comparison

Last Updated on: Aug 02, 2025

Key Highlights

  • The Latest Trading Price of Bliss GVS Pharma Ltd is ₹ 173.7 as of 01 Aug 15:30.
  • The P/E Ratio of Bliss GVS Pharma Ltd changed from 10.7 on March 2020 to 14.7 on March 2025 . This represents a CAGR of 5.44% over 6 yearsThe P/E Ratio of Medicamen Biotech Ltd changed from 16.6 on March 2020 to 0 on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The Market Cap of Bliss GVS Pharma Ltd changed from ₹ 1039 crore on March 2020 to ₹ 1238 crore on March 2025 . This represents a CAGR of 2.96% over 6 yearsThe Market Cap of Medicamen Biotech Ltd changed from ₹ 220.75 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The revenue of Bliss GVS Pharma Ltd for the Jun '25 is ₹ 242.92 crore as compare to the Mar '25 revenue of ₹ 210.05 crore. This represent the growth of 15.65% The revenue of Medicamen Biotech Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 34.84 crore. This represent the decline of -100%.
  • The ebitda of Bliss GVS Pharma Ltd for the Jun '25 is ₹ 76.78 crore as compare to the Mar '25 ebitda of ₹ 33.15 crore. This represent the growth of 131.61% The ebitda of Medicamen Biotech Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 3.62 crore. This represent the decline of -100%.
  • The net profit of Bliss GVS Pharma Ltd changed from ₹ 14.37 crore to ₹ 44.36 crore over 9 quarters. This represents a CAGR of 65.03% The net profit of Medicamen Biotech Ltd changed from ₹ 3.95 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% .
  • The Dividend Payout of Bliss GVS Pharma Ltd changed from 5.58 % on March 2020 to 7.64 % on March 2025 . This represents a CAGR of 5.38% over 6 yearsThe Dividend Payout of Medicamen Biotech Ltd changed from 4.98 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Bliss GVS Pharma Ltd

  • Bliss GVS Pharma Limited was originally incorporated as a Private Limited Company in the name of Bliss Chemicals & Pharmaceuticals India Private Limited in 1984.
  • The status converted into a Public Limited Company and the name of the Company was changed to Bliss Chemicals & Pharmaceuticals India Limited and further to Bliss GVS Pharma Limited on May 12, 2006. The Company, founded in 1984 with the objective of ensuring healthcare access worldwide, is one of the pharmaceutical industries' fastest-growing businesses.
  • The Company has a robust portfolio of more than 250 products and is a global leader in the dosage forms for suppositories and pessaries.
  • It has a strong foothold in Sub Saharan Africa.
  • The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

About Medicamen Biotech Ltd

  • A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
  • The Company has presence in 40+ countries.
  • Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
  • MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
  • The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

Bliss GVS Pharma Ltd News Hub

News

Bliss GVS Pharma Ltd leads gainers in 'B' group

Foseco India Ltd, Saurashtra Cement Ltd, Omax Autos Ltd and Manaksia Aluminium Company Ltd...

Read more

30 Jul 2025 12:15

News

Bliss GVS Pharma to table results

Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 29 July 2...

Read more

23 Jul 2025 09:49

News

Bliss GVS Pharma Ltd leads gainers in 'B' group

Northern ARC Capital Ltd, Apollo Micro Systems Ltd, IRM Energy Ltd and Malu Paper Mills Lt...

Read more

23 Jun 2025 12:15

News

Bliss GVS Pharma allots 75,250 equity shares under ESOP

Bliss GVS Pharma has allotted 75,250 equity shares under ESOP on 06 June 2025. Consequentl...

Read more

06 Jun 2025 13:51

News

Board of Bliss GVS Pharma recommends final dividend

Bliss GVS Pharma announced that the Board of Directors of the Company at its meeting held ...

Read more

13 May 2025 09:26

News

Bliss GVS Pharma schedules AGM

Bliss GVS Pharma announced that the 40th Annual General Meeting(AGM) of the company will b...

Read more

13 May 2025 12:51

Medicamen Biotech Ltd News Hub

News

Medicamen Biotech rallies after securing USFDA approval for Bortezomib injection

The ANDA pertains to Bortezomib for Injection, 3.5 mg single-dose vial. The USFDA has dete...

Read more

03 Jun 2025 13:07

News

Board of Medicamen Biotech recommends final dividend

Medicamen Biotech announced that the Board of Directors of the Company at its meeting held...

Read more

31 May 2025 12:29

News

Medicamen Biotech to hold board meeting

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 30 May 2...

Read more

23 May 2025 20:27

News

Medicamen Biotech to convene EGM

Medicamen Biotech announced that an Extra Ordinary General Meeting (EGM) of the Company wi...

Read more

27 Feb 2025 16:47

News

Medicamen Biotech announces board meeting date

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 26 Febru...

Read more

21 Feb 2025 19:50

News

Medicamen Biotech to declare Quarterly Results

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 11 Febru...

Read more

05 Feb 2025 14:45

SWOT Analysis Of Medicamen Biotech Ltd

Strength

4

S

Weakness

0

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Bliss GVS Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Medicamen Biotech Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Bliss GVS Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Bliss GVS Pharma Ltd and Medicamen Biotech Ltd

Which company has a larger market capitalization, Bliss GVS Pharma Ltd or Medicamen Biotech Ltd?

Market cap of Bliss GVS Pharma Ltd is 1,832 Cr while Market cap of Medicamen Biotech Ltd is 521 Cr

What are the key factors driving the stock performance of Bliss GVS Pharma Ltd and Medicamen Biotech Ltd?

The stock performance of Bliss GVS Pharma Ltd and Medicamen Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bliss GVS Pharma Ltd and Medicamen Biotech Ltd?

As of August 2, 2025, the Bliss GVS Pharma Ltd stock price is INR ₹173.7. On the other hand, Medicamen Biotech Ltd stock price is INR ₹384.55.

How do dividend payouts of Bliss GVS Pharma Ltd and Medicamen Biotech Ltd compare?

To compare the dividend payouts of Bliss GVS Pharma Ltd and Medicamen Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions